<DOC>
	<DOCNO>NCT02448589</DOCNO>
	<brief_summary>A Phase 1 , Open-Label , Non-Randomized , Dose-Escalating Safety , Tolerability , Pharmacokinetic Pharmacodynamic Study TAS-119 Patients Advanced Solid Tumors .</brief_summary>
	<brief_title>An Investigation TAS-119 Monotherapy Combination With Docetaxel</brief_title>
	<detailed_description>This Phase 1 , open-label , non-randomized , dose escalation study TAS-119 evaluate safety , tolerability , PK , pharmacogenomics , pharmacodynamics , preliminary antitumour activity patient advance unresectable solid tumour . The study evaluate TAS-119 monotherapy , employ two sequential phase . - A Dose Escalation Phase - An Expansion Phase</detailed_description>
	<criteria>Inclusion criterion include follow : 1 . Is male female , â‰¥ 18 year age , provide write informed consent . 2 . Has histologically cytologically confirm advanced , unresectable , metastatic solid tumor ( ) patient available therapy likely provide clinical benefit . 3 . Must archival FFPE tumor sample available , provide Sponsor upon request . 4 . In Expansion Phase : patient willing undergo tumor core biopsy procedure pretreatment Day 4 , Cycle 1 , judgment investigator , consider clinically safe appropriate . This requirement optional preferred patient Dose Escalation . 5 . Has adequate organ function . Women childbearing potential must negative pregnancy test ( urine serum ) within 7 day prior start study drug . Both male female must agree use effective birth control study conception possible interval . Exclusion : 1 . Has receive prior treatment TAS119 . 2 . Has receive treatment proscribed treatment within specified time frame prior study drug administration . 3 . Has serious illness medical condition ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Dose Expansion</keyword>
	<keyword>MTD</keyword>
	<keyword>TAS-119</keyword>
	<keyword>Aurora A Kinase Inhibitor</keyword>
</DOC>